HC Wainwright Reaffirms Buy Rating for Palvella Therapeutics (NASDAQ:PVLA)

Palvella Therapeutics (NASDAQ:PVLA)‘s stock had its “buy” rating restated by HC Wainwright in a research note issued on Friday,Benzinga reports. They currently have a $38.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 172.01% from the company’s current price.

Separately, Cantor Fitzgerald assumed coverage on Palvella Therapeutics in a research report on Wednesday, December 18th. They set an “overweight” rating on the stock.

Palvella Therapeutics Stock Down 2.0 %

Palvella Therapeutics stock opened at $13.97 on Friday. The firm has a market cap of $18.44 million, a price-to-earnings ratio of -1.15 and a beta of 0.67. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $22.32.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins bought 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The shares were purchased at an average cost of $12.93 per share, with a total value of $51,720.00. Following the transaction, the director now directly owns 180,671 shares in the company, valued at approximately $2,336,076.03. The trade was a 2.26 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 6.39% of the company’s stock.